Myriad Genetics, Inc. $MYGN Position Increased by Farther Finance Advisors LLC

Farther Finance Advisors LLC increased its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 6,192.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,349 shares of the company’s stock after purchasing an additional 5,264 shares during the period. Farther Finance Advisors LLC’s holdings in Myriad Genetics were worth $28,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Jennison Associates LLC lifted its holdings in shares of Myriad Genetics by 3.0% in the 1st quarter. Jennison Associates LLC now owns 60,811 shares of the company’s stock worth $539,000 after purchasing an additional 1,796 shares during the last quarter. Natixis Advisors LLC lifted its holdings in shares of Myriad Genetics by 1.3% in the 1st quarter. Natixis Advisors LLC now owns 212,138 shares of the company’s stock worth $1,882,000 after purchasing an additional 2,810 shares during the last quarter. GAMMA Investing LLC raised its stake in Myriad Genetics by 520.8% during the 1st quarter. GAMMA Investing LLC now owns 4,470 shares of the company’s stock valued at $40,000 after acquiring an additional 3,750 shares in the last quarter. State of Wyoming raised its stake in Myriad Genetics by 147.0% during the 1st quarter. State of Wyoming now owns 8,641 shares of the company’s stock valued at $77,000 after acquiring an additional 5,143 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in Myriad Genetics by 57.0% during the 1st quarter. Blue Trust Inc. now owns 14,367 shares of the company’s stock valued at $127,000 after acquiring an additional 5,214 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics Stock Performance

MYGN opened at $7.64 on Thursday. Myriad Genetics, Inc. has a one year low of $3.76 and a one year high of $26.52. The stock’s fifty day moving average is $6.57 and its 200-day moving average is $6.16. The company has a market capitalization of $710.86 million, a PE ratio of -1.79 and a beta of 1.97.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Myriad Genetics in a research note on Saturday, September 27th. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Myriad Genetics currently has a consensus rating of “Hold” and an average target price of $12.45.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.